Details for Patent: 6,652,880

« Back to Dashboard

Which drugs does patent 6,652,880 protect, and when does it expire?

Patent 6,652,880 protects TAYTULLA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.

Summary for Patent: 6,652,880

Title:	Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
Abstract:	This invention is directed to pharmaceutical compositions for oral administration, wherein the drug or active ingredient is known to have stability problems associated with the use of free fatty acids. The compositions of the invention enhance the solubility of such compounds and improve the storage stability thereof and can be advantageously used in soft-gel and hard-shell capsular formulations. The liquid pharmaceutical compositions, according to the present invention, have a drug dissolved in a liquid vehicle. The liquid vehicle comprising a glyceride of a long chain fatty acid and a lypophilic surfactant having an HLB of less than ten. The composition, according to the invention, is also substantially free of free fatty acids.
Inventor(s):	Aylwin; Elizabeth Anne (Swindon, GB), Banbury; Susan (Cheltenham, GB), Ferdinando; Josephine Joan Christine (Tadley, GB), de Nijs; Henrik (Oss, NL)
Assignee:	R.P. Scherer Technologies, Inc. (Paradise Valley, NV)
Application Number:	09/914,576
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	RS	Patent No.	Patent Expiration	Product
Apil	TAYTULLA	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	204426-001	Apr 19, 2013	RX	Yes	Yes	► Subscribe	► Subscribe	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,652,880

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9907715	Apr 01, 1999

PCT Information
PCT Filed	March 29, 2000	PCT Application Number:	PCT/US00/08426
PCT Publication Date:	October 12, 2000	PCT Publication Number:	WO00/59482

International Patent Family for Patent: 6,652,880

Country	Document Number	Estimated Expiration
Russian Federation	2207859	► Subscribe
Poland	196823	► Subscribe
Poland	350094	► Subscribe
New Zealand	514649	► Subscribe
Norway	331396	► Subscribe
Norway	20014719	► Subscribe
Mexico	PA01009817	► Subscribe
Japan	4636692	► Subscribe
Japan	2003526620	► Subscribe
Israel	145567	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview